about
Cannabinoids in health and diseaseReduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticityThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinThe endocannabinoid system as an emerging target of pharmacotherapyThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetSystematic Review of Pharmacological Properties of the Oligodendrocyte LineageRecent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiologyGenetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice.Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsyIn vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityTargeting the endocannabinoid system in Alzheimer's disease.In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivoThe decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ anThe CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury.The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's diseaseEndocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults.Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis.The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?The expanding field of cannabimimetic and related lipid mediators.Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ.Cannabinoid agonist rescues learning and memory after a traumatic brain injuryCannabinoid receptors and endocannabinoids: evidence for new players.Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsNew insights on endocannabinoid transmission in psychomotor disorders.The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiationBlood pressure regulation by endocannabinoids and their receptorsCannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice.The use of cannabinoids in multiple sclerosis.Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expressionEndocannabinoids and the haematological system.New horizons for newborn brain protection: enhancing endogenous neuroprotectionThe endocannabinoid system: current pharmacological research and therapeutic possibilities.Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptorEndocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioningCannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury
P2860
Q24633884-0487D963-5363-4AB9-B30A-DAF51909DEF9Q24642505-51D23130-1123-4DFA-B4EB-6FBDE033F080Q24643876-60C6AE69-60A8-4A88-94A2-33E37699740FQ24648473-5B2906EA-6489-4D19-A373-247D7346E5E9Q24650098-F6BE17C9-B805-4972-98A7-A2569B9A505DQ26768210-3FE56EA1-8452-48ED-938D-0CD6EB7C1751Q28260273-29A47767-E3A9-48F7-A910-4254F9DAC4B0Q28469322-CD257DD0-A7C7-4090-B789-7C7C86CBDF3AQ30506148-3BEA1C92-8E5B-41B5-AA87-3D727F1C04A9Q33586242-672BDA88-F89F-4C2A-8C0B-3014D52C832CQ33751118-83FBFD69-27CD-4820-99B7-6157DE9F6AEBQ33930000-449BC4E2-2E5F-4B01-A339-FE92830E7382Q33944886-86F5F853-D320-4C22-A3EA-787F9C181714Q34098196-7D6473F8-5F05-4028-A3E0-A408388FD83CQ34160453-ABFE5C26-45FC-48EE-8DC9-7557CC5F107FQ34267133-C627400C-26CB-4FA8-9844-9ED34DA19C15Q34589360-D46DB68C-FC86-4696-88F8-A8936D889E31Q34591087-42958AA4-AF43-4D1A-A9E4-19FC8F5AA1A2Q34626755-66890442-5A07-42B3-BACC-70FDEB1112EEQ34627188-E5BFD324-1308-472E-99DB-FA72779E6604Q34642593-4B4A53E0-5295-4EFB-88A7-4789A386E2ADQ34695691-47C2B4F7-4007-42D9-99A3-0016708F67CBQ35030056-8C194A48-5046-4362-9BE1-CBAFF1219438Q35048658-FAEEF40E-6E20-4C01-8A5B-506371B09DF5Q35193317-73C73CCF-F8FF-4964-BAE9-896A7F9F8829Q35204889-1D0257FB-EFC0-42E0-8F66-D7A860026027Q35594830-CADBF59E-542F-42F3-B0DD-53BE3204521BQ36052772-095A4D2C-5CA9-4844-BD05-C679B6E64A81Q36074595-D3C63461-071B-40A9-9817-BC5ECC09C52CQ36130163-1A647932-5F62-4FC6-BCF8-49A91CE7CBF0Q36135785-C655CDB9-4D7A-4C60-8752-7129002E9C54Q36166294-15A2B7D4-4716-48D5-8580-226200015A52Q36196473-C840873C-2D67-47D8-83BF-38E5D09F72FFQ36358055-81AA63C4-10EF-4741-AB7F-60480ADDB624Q36358723-D0DD253C-9E5A-4ACC-B768-9ED2293183D7Q36374839-7CCB86DA-C5C0-4B5C-B471-A082B44E2BD7Q36381416-E27F78C1-1F07-4E54-A0DC-36642B5175FEQ36416340-5230D152-1015-41B6-9C12-4212BA4F3814Q36416372-AAA48D7A-696B-48EE-B9C9-2BA423EF99C6Q36431793-5FCEC8B4-56DE-4C08-8B5E-6BDF0712F088
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cannabinoids and neuroinflammation.
@en
type
label
Cannabinoids and neuroinflammation.
@en
prefLabel
Cannabinoids and neuroinflammation.
@en
P2860
P356
P1476
Cannabinoids and neuroinflammation.
@en
P2093
Lisa Walter
Nephi Stella
P2860
P304
P356
10.1038/SJ.BJP.0705667
P407
P577
2004-02-02T00:00:00Z